HOME >> BIOLOGY >> NEWS
Army awards up to $50 million to establish Institute for Collaborative Biotechnologies

newly incorporated atoms provide new functionality including controlled mechanical properties and enhanced thermal and chemical stability.

The research plan for the Institute for Collaborative Biotechnologies will be organized around three emphases:

(1) Sensors, Electronics and Information Processing, led by UCSB Chemistry and Materials Professor Guillermo Bazan. Research will focus on the development of sensors using biological molecules and paradigms for sensing with unprecedented sensitivity, accuracy, and speed and the translation of information from sensors into electronic information for real-time sensing and response capabilities.

(2) Biotechnological and Biologically Inspired Routes to Electronic, Optical and Magnetic Materials, led by Morse. Research will investigate the use of biological mechanisms and biomolecular mechanisms to control nanofabrication of new materials for electronic, optical, and optoelectronic activity, including new approaches to the generation of electrical energy and portable sources of energy such as would be carried for defense applications.

(3) Biotechnological and Biologically Inspired New Routes to Information Professing, led by UCSB Physics and Electrical and Computer Engineering Professor David Awschalom and Electrical and Computer Engineering Professor Evelyn Hu. Research seeks to use biological systems to guide the development of new routes for information processing. Molecular signaling and recognition and integration of information will be considered from both the perspective of the small world of molecules but also from the macroscopic perspective of ecosystems. Awschalom heads the UCSB Center for Spintronics and Quantum Computing. Hu is UCSB's science director for the California NanoSystems Institute (CNSI), whose state-of the-art research facilities, nearing the construction phase, will greatly enhance the ability of ICB researchers at UCSB to advance their cross-disciplinary researc
'"/>

Contact: Jacquelyn Savani
jsavani@engineering.ucsb.edu
805-893-4301
University of California, Santa Barbara - Engineering
27-Aug-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. NSF awards 22 new projects for plant genome research
4. The American Phytopathological Society announces 2004 awards
5. NSF announces six FIBR awards to tackle some of biologys most challenging questions
6. Two Virginia Tech energy-related inventions win R&D 100 awards
7. APS awards more than $140,000 to minority students of physiology
8. APS awards more than $36,000 to its 2004 undergraduate research fellows
9. 8 environmental stewards win $900,000 in biodiversity awards
10. UCSB professor and director receives two national awards
11. NSF awards $10 million in grants to ocean sites for long-term ecological research

Post Your Comments:
(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
(Date:3/29/2015)... March 29, 2015 As a symbol ... required by our pharmaceutical manufacturing clients, Whitehouse Laboratories is ... of the Berkenstock Race Team for the 2015 race ... only speed, but a strong sense of precision and ... lead to success in the quality control testing laboratory. ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
Cached News: